Inside CKD:多国慢性肾脏病筛查的成本效益分析
本研究基于Inside CKD微观模拟模型,在31个国家或地区评估全人群及高危人群的慢性肾脏病筛查策略的成本效益。结果显示,对≥45岁普通人群采用「2次eGFR加1次UACR」策略在所有国家均具成本效益,且诊断率显著提高。
要点
- ≥45岁普通人群采用「2次eGFR加1次UACR」筛查在所有国家均具成本效益。
- 「2次eGFR加1次UACR」策略的成本效益始终高于仅「2次eGFR」策略。
- 筛查使每10万 eligible 人群的CKD诊断率从459升至7475或14392。
核心结论
- CKD筛查在全球普通人群中可能具有成本效益,包括≥45岁人群。
- 分析支持全球指南关于同时检测eGFR和UACR的建议,但需结合当地因素。
研究设计与样本
- 使用已发表的Inside CKD微观模拟,在31个国家或地区模拟虚拟封闭人群,采用终身时间范围。
- 考虑普通人群≥65岁或≥45岁,以及高危亚组(2型糖尿病、高血压或心血管疾病)。
- 比较「2次eGFR」、「2次eGFR加1次UACR」与当前实践,合格患者接受RASi治疗。
主要发现
- ≥45岁普通人群采用「2次eGFR加1次UACR」策略在所有国家或地区均具成本效益。
- 仅「2次eGFR」策略在除1个国家外的所有国家具成本效益。
- 「2次eGFR加1次UACR」策略的成本效益始终更高。
- ≥45岁普通人群筛查使每10万 eligible 人群的CKD诊断率从当前实践的459升至仅「2次eGFR」的7475或「2次eGFR加1次UACR」的14392。
- ≥65岁人群的成本效益和诊断率趋势相似。
关键数值与推荐
- 筛查策略包括2次血清肌酐检测评估eGFR(「2次eGFR」)或额外加1次尿白蛋白肌酐比检测(「2次eGFR加1次UACR」)。
- 合格患者接受肾素-血管紧张素系统抑制剂(RASi)治疗。
临床怎么用
- 对≥45岁普通人群可考虑同时检测eGFR和UACR以筛查CKD,但需结合当地因素。
- 高危人群(2型糖尿病、高血压、心血管疾病)的筛查策略可参考普通人群结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Early detection of chronic kidney disease (CKD) could slow its progression; however, most patients in earlier stages remain undiagnosed. Our study objective was to assess the cost-effectiveness of multinational CKD screening strategies from the payer perspective across general and higher-risk populations. METHODS: Using the published Inside CKD microsimulation, we projected virtual closed populations to assess CKD screening strategies in 31 countries or regions over a lifetime horizon. We considered people aged ≥ 65 or ≥ 45 years in the general population and in high-risk subgroups (type 2 diabetes [T2D], hypertension, or cardiovascular disease [CVD]). Simulated populations could receive 2 serum creatinine (SCr) tests assessing estimated glomerular filtration rate (eGFR), "2 eGFR only", or an additional urinary albumin-to-creatinine ratio test (UACR), "2 eGFR and 1 UACR", versus current practice. Eligible patients received renin-angiotensin system inhibitors (RASi). RESULTS: Screening the general population aged ≥ 45 years for CKD was cost-effective versus current practice in all countries or regions using the "2 eGFR and 1 UACR" strategy, and cost-effective in all but 1 country using the 2 eGFR only strategy. The 2 eGFR and 1 UACR strategy showed consistently higher cost-effectiveness. Screening general populations aged ≥ 45 years increased projected CKD diagnosis rates per 100,000 persons eligible for screening from 459 by current practice to 7475 patients using 2 eGFR only, or 14,392 using 2 eGFR and 1 UACR. Similar trends in cost-effectiveness and diagnosis rates were observed in persons aged ≥ 65 years. CONCLUSION: CKD screening may be cost-effective in general populations worldwide, including in populations aged ≥ 45 years. Our analysis corroborates global guideline recommendations for simultaneous eGFR and UACR testing if considered in the context of local factors.
引用
- Tangri N, Oh KH, Choo JCJ, et al. Inside CKD: Cost-Effectiveness of Multinational Screening for CKD. Kidney Int Rep. 2025. PMID: 40303204. doi:10.1016/j.ekir.2025.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。